Cisplatin for Mesothelioma

Cisplatin is a platinum-based chemotherapy drug that serves as the backbone of standard first-line treatment for malignant pleural mesothelioma. As an alkylating-like agent, cisplatin works by forming crosslinks within DNA strands, which prevents cancer cells from replicating their genetic material and ultimately triggers programmed cell death (apoptosis). It has been used in oncology since its FDA approval in 1978 and remains one of the most widely used chemotherapy agents worldwide.¹

In mesothelioma treatment, cisplatin is rarely used alone. Its primary role is as the platinum partner in combination regimens — most commonly paired with pemetrexed (Alimta), which together form the only FDA-approved chemotherapy regimen for malignant pleural mesothelioma. The landmark Vogelzang trial demonstrated that pemetrexed plus cisplatin improved median overall survival to 12.1 months compared to 9.3 months with cisplatin alone, establishing this doublet as the global standard of care.²

Cisplatin's mechanism of action is distinct from pemetrexed's antifolate activity, which is why the two drugs work synergistically. While pemetrexed disrupts nucleotide synthesis (the production of DNA building blocks), cisplatin directly damages existing DNA by forming platinum-DNA adducts — chemical bonds between platinum atoms and purine bases on the DNA strand. These adducts distort the DNA helix and block replication, forcing the cell into apoptosis. Cancer cells that are actively dividing are most vulnerable to this mechanism.¹

While cisplatin is highly effective, its use is limited by significant toxicities — particularly kidney damage (nephrotoxicity), hearing loss (ototoxicity), and nerve damage (peripheral neuropathy). These side effects require careful monitoring and aggressive supportive care, including extensive intravenous hydration before and after each infusion. For patients who cannot tolerate cisplatin, carboplatin is used as an alternative platinum agent with a more manageable side effect profile.³

Cisplatin is the platinum component of several mesothelioma treatment regimens, all of which are administered intravenously in an outpatient or inpatient infusion setting:²

First-Line: Cisplatin + Pemetrexed

The standard first-line regimen, supported by level 1 evidence from the EMPHACIS trial:²

• Cisplatin — 75 mg/m² intravenously on Day 1, administered approximately 30 minutes after pemetrexed
• Pemetrexed — 500 mg/m² intravenously on Day 1
• Cycle — Every 21 days for 4–6 cycles
• Hydration protocol — 1–2 liters of normal saline before cisplatin, plus post-infusion hydration, to protect the kidneys
• Anti-emetics — Cisplatin is highly emetogenic; a 3-drug regimen (NK1 antagonist + 5-HT3 antagonist + dexamethasone) is standard

Triplet Therapy: Cisplatin + Pemetrexed + Bevacizumab

The MAPS trial demonstrated that adding bevacizumab to pemetrexed/cisplatin improved median overall survival to 18.8 months compared to 16.1 months with chemotherapy alone. This triplet regimen is used in selected patients with good performance status and no contraindications to anti-VEGF therapy.⁴

HIPEC Protocols

In peritoneal mesothelioma, cisplatin is commonly used in heated intraperitoneal chemotherapy (HIPEC) during cytoreductive surgery. Cisplatin is heated to 41–43°C and circulated directly within the abdominal cavity for 60–90 minutes after maximal surgical debulking. The combination of heat and direct drug contact enhances cisplatin's cytotoxic effect on remaining microscopic disease.⁵

Clinical Trial Results

• Cisplatin alone — Median survival approximately 9.3 months, response rate 16.7%
• Cisplatin + pemetrexed — Median survival 12.1 months, response rate 41.3%
• Cisplatin + pemetrexed + bevacizumab — Median survival 18.8 months (MAPS trial)

Cisplatin-based chemotherapy remains the most effective systemic treatment for mesothelioma, though outcomes vary based on several factors:²

• Histologic subtype — Patients with epithelioid mesothelioma respond best to cisplatin-based therapy, with higher response rates and longer survival than sarcomatoid or biphasic subtypes
• Performance status — Patients with good baseline functional status (ECOG 0–1) tolerate cisplatin better and derive greater benefit
• Multimodal approach — Cisplatin-based chemotherapy combined with surgery and/or radiation in selected patients may extend survival beyond what chemotherapy alone achieves
• Age and renal function — Older patients or those with pre-existing kidney disease may benefit more from substituting carboplatin, which has comparable efficacy with less renal toxicity

Cisplatin's side effects require proactive management and close monitoring throughout treatment:³

• Nephrotoxicity (kidney damage) — The most serious dose-limiting toxicity. Aggressive hydration with intravenous saline before and after each infusion is mandatory. Serum creatinine and electrolytes are checked before every cycle. Patients should drink at least 2–3 liters of fluid daily and avoid nephrotoxic medications (NSAIDs, aminoglycosides)
• Nausea and vomiting — Cisplatin is among the most emetogenic chemotherapy drugs. A triple anti-emetic regimen is given preventively: an NK1 receptor antagonist (aprepitant or fosaprepitant), a 5-HT3 antagonist (ondansetron or palonosetron), and dexamethasone. Breakthrough nausea is managed with additional agents
• Ototoxicity (hearing loss) — Cisplatin can cause permanent high-frequency hearing loss and tinnitus. Baseline and periodic audiometry testing is recommended. Hearing damage is cumulative and dose-dependent, and is one of the most common reasons for switching to carboplatin
• Peripheral neuropathy — Numbness, tingling, and pain in the hands and feet affect 30–40% of patients and can persist long after treatment ends. Dose reduction or discontinuation may be necessary for severe neuropathy
• Electrolyte disturbances — Cisplatin causes magnesium and potassium wasting through the kidneys. Regular electrolyte monitoring and oral or intravenous supplementation are standard parts of the treatment protocol
• Myelosuppression — Moderate suppression of blood cell production occurs, requiring blood count monitoring before each cycle. Neutropenia increases infection risk; patients should avoid crowds during count nadirs (typically days 7–14)